Publications by authors named "Regina A Swift"

Claim this Profile
A
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
James R Berenson, Clara Kim, Sean Bujarski, Jennifer To, Tanya M Spektor, Regina A Swift

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Jonathan Afari, Tanya M Spektor, Carley Turner, Alexa Cohen, Alberto Bessudo, Regina A Swift

Exp Hematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
David Daniely, Eli Forouzan, Tanya M Spektor, Alexa Cohen, Jacob D Bitran, Regina A Swift

Exp Hematol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
David Yashar, Tanya M Spektor, Daisy Martinez, Matthew Ghermezi, Regina A Swift

Leuk Lymphoma· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Sean Bujarski, Christine Sutanto, Tanya M Spektor, Jennifer To, Regina A Swift

Hematol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Sean Bujarski, Marissa-Skye Goldwater, Bernard Sean Regidor, Scott Jew, David Daniely, Regina A Swift

Eur J Haematol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
James R Berenson, Jennifer To, Tanya M Spektor, Daisy Martinez, Carley Turner, Regina A Swift

Clin Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Alexa Cohen, Tanya M Spektor, Laura Stampleman, Alberto Bessudo, Peter J Rosen, Regina A Swift

Br J Haematol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Aleksandra P Vidisheva, James Wang, Tanya M Spektor, Jacob D Bitran, Jose Lutzky, Regina A Swift

Support Care Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Regina A Swift

Haematologica· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.
Austin A Robinson, James Wang, Suzie Vardanyan, Erik K Madden, Frank Hebroni, Regina A Swift

Eur J Haematol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
James Wang, Kyle A Udd, Aleksandra Vidisheva, Regina A Swift, Tanya M Spektor

Support Care Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.
James R Berenson, Ori Yellin, Hesaraghatta K Shamasunder, Chien-Shing Chen, Veena Charu, Regina A Swift

Support Care Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
James R Berenson, James D Hilger, Ori Yellin, Ralph V Boccia, Jeffrey Matous, Regina A Swift

Ann Hematol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
James R Berenson, Ori Yellin, Alberto Bessudo, Ralph V Boccia, Stephen J Noga, Regina A Swift

Br J Haematol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Eric Sanchez, Mingjie Li, Alex Kitto, Jennifer Li, Cathy S Wang, Regina A Swift

Br J Haematol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
James R Berenson, Ori Yellin, Chien-Shing Chen, Ravi Patel, Alberto Bessudo, Regina A Swift

Br J Haematol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metatarsal stress fractures in patients with multiple myeloma treated with long-term bisphosphonates: a report of six cases.
Gabriel N Waterman, Ori Yellin, Kamran Jamshidinia, Regina A Swift, James A Tamkin

J Bone Joint Surg Am· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Gabriel N Waterman, Ori Yellin, Regina A Swift, Russell Mapes, Benjamin Eades

Ann Hematol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
James R Berenson, Ori Yellin, John Crowley, Adel Makary, Donald S Gravenor, Regina A Swift

Am J Hematol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
James R Berenson, Ori Yellin, Donald Woytowitz, Marshall S Flam, Alan Cartmell, Regina A Swift

Eur J Haematol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
James R Berenson, Ori Yellin, Ravi Patel, Herb Duvivier, Youram Nassir, Regina A Swift

Clin Cancer Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
James R Berenson, Ori Yellin, Ralph V Boccia, Marshall Flam, Siu-Fun Wong, Regina A Swift

Clin Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
James R Berenson, Jeffrey Matous, Regina A Swift, Russell Mapes, Blake Morrison

Clin Cancer Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
James R Berenson, Ralph Boccia, David Siegel, Marek Bozdech, Alberto Bessudo, Regina A Swift

Br J Haematol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis